Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.98 |
| ▸ | KDR | P35968 | 2/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.82 |
| ▸ | AURKA | O14965 | 1/20 | 0.82 |
| ▸ | INSR | P06213 | 1/20 | 0.82 |
| ▸ | FBP1 | P09467 | 1/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.82 |
| ▸ | FLT4 | P35916 | 1/20 | 0.82 |
| ▸ | CLK1 | P49759 | 1/20 | 0.82 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.82 |
| ▸ | TEK | Q02763 | 1/20 | 0.82 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14092460 | 0.97 | EGFR (0.92) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL30520472 | 0.94 | EGFR (0.87) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL13524614 | 0.94 | EGFR (0.87) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL30207668 | 0.93 | EGFR (0.85) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL28520911 | 0.93 | EGFR (0.85) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL31491085 | 0.93 | EGFR (0.85) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL14964773 | 0.93 | EGFR (0.85) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL18978997 | 0.92 | EGFR (0.89) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL31213839 | 0.92 | EGFR (0.84) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL5911655 | 0.92 | EGFR (0.86) | EGFRKDRERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | EGFR 493/4885KDR 1628/4885ERBB2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.